Bishop MR et al. Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma. N Engl J Med 2022;386(7):629-39. Abstract
Brem EA et al. SWOG 1918: A phase II/III randomized study of R-miniCHOP with or without oral azacitidine (CC-486) in participants age 75 years or older with newly diagnosed aggressive non-Hodgkin lymphomas – Aiming to improve therapy, outcomes, and validate a prospective frailty tool. J Geriatr Oncol 2022;13(2):258-64. Abstract
Brem EA et al. S1918: A phase II/III randomized study of R-minichop with or without oral azacitidine (CC-486) in participants age 75 years or older with newly diagnosed diffuse large B cell lymphoma, grade IIIb follicular lymphoma, transformed lymphoma, and high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements. ASH 2021;Abstract 3565.
Budde LE et al. Mosunetuzumab monotherapy is an effective and well-tolerated treatment option for patients with relapsed/refractory (R/R) follicular lymphoma (FL) who have received ≥ 2 prior lines of therapy: Pivotal results from a phase I/II study. ASH 2021;Abstract 127.
Cahill KE, Smith SM. Follicular lymphoma: A focus on current and emerging therapies. Oncology (Williston Park). 2022;36(2):97-106. Abstract
Cahill K et al. A multicenter, single-arm, Phase I/II dose finding and efficacy study of venetoclax, CC-486, and obinutuzumab in minimally-pretreated follicular lymphoma. ASH 2021;Abstract 2420.
Caimi PF et al. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): A multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol 2021;22(6):790-800. Abstract
Carlo-Stella C et al. Planned interim analysis of a phase 2 study of loncastuximab tesirine plus ibrutinib in patients with advanced diffuse large B-cell lymphoma (LOTIS-3). ASH 2021;Abstract 54.
Fowler NH et al. Umbralisib, a dual PI3K-delta/CK1-epsilon inhibitor in patients with relapsed or refractory indolent lymphoma. J Clin Oncol 2021;39(15):1609-18. Abstract
Goldman A et al. Adverse cardiovascular and pulmonary events associated with chimeric antigen receptor T-cell therapy. J Am Coll Cardiol 2021;78(18):1800-13. Abstract
Hutchings M et al. Glofitamab (glofit) in combination with polatuzumab vedotin (pola): Phase Ib/II preliminary data support manageable safety and encouraging efficacy in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). ASH 2021;Abstract 525.
Hutchings M et al. Glofitamab, a novel, bivalent CD20-targeting T-cell-engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: A phase I trial. J Clin Oncol 2021;39(18):1959-70. Abstract
Jacobson C et al. Long-term (4- and 5-year) overall survival in ZUMA-1, the pivotal study of axicabtagene ciloleucel (axi-cel) in patients with refractory large B-cell lymphoma (LBCL). ASH 2021;Abstract 1764.
Kamdar M et al. Lisocabtagene maraleucel (liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, versus standard care (SOC) with salvage chemotherapy (CT) followed by autologous stem cell transplantation (ASCT) as second-line (2L) treatment in patients (pts) with relapsed or refractory (R/R) large B-cell lymphoma (LBCL): Results from the randomized phase 3 Transform study. ASH2021;Abstract 91.
Kumar A et al. Brentuximab vedotin combined with chemotherapy in patients with newly diagnosed early-stage, unfavorable-risk Hodgkin lymphoma. J Clin Oncol 2021;39(20):2257-65. Abstract
Kuruvilla J et al. Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): An interim analysis of a multicentre, randomised, open-label, phase 3 study. Lancet Oncol 2021;22(4):512-24. Abstract
Locke FL et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N Engl J Med 2021;386(7):640-54. Abstract
Major A, Smith SM. DA-R-EPOCH vs R-CHOP in DLBCL: How do we choose? Clin Adv Hematol Oncol 2021;19(11):698-709. Abstract
Matasar MJ et al. Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): A double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 2021;22(5):678-89. Abstract
Minson A et al. Trial in progress: A multicentre, parallel arm, open-label trial of frontline R-CHOP/polatuzumab vedotin-RCHP and glofitamab in younger patients with higher risk diffuse large B-cell lymphoma (COALITION). ASH 2021;Abstract 3571.
Morschhauser F et al. Glofitamab as monotherapy and in combination with obinutuzumab induces high complete response rates in patients (pts) with multiple relapsed or refractory (R/R) follicular lymphoma (FL). ASH2021;Abstract 128.
Mushi PN et al. ASTCT, CIBMTR, and EBMT clinical practice recommendations for transplant and cellular therapies in mantle cell lymphoma. Bone Marrow Transplant 2021;56(12):2911-21. Abstract
Neelapu SS et al. Long-term follow-up analysis of ZUMA-5: A phase 2 study of axicabtagene ciloleucel (axi-cel) in patients with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL). ASH 2021;Abstract 93.
Orellana-Noia VM et al. Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: Real-world outcomes from 21 US academic institutions. Blood 2022;139(3):413-23. Abstract
Riedell PA et al. Bloodless chimeric antigen receptor (CAR) T-cell therapy in Jehovah’s Witnesses. Leuk Lymphoma 2021;62(6):1497-501. Abstract
Rojek AE, Smith SM. Evolution of therapy for limited stage diffuse large B-cell lymphoma. Blood Cancer J 2022;12(2):33. Abstract
Rule S et al. Efficacy and safety assessment of prolonged maintenance with subcutaneous rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma: Results of the phase III MabCute study. Haematologica 2022;107(2):500-9. Abstract
Salles G et al. Efficacy comparison of tisagenlecleucel versus standard of care in patients with relapsed or refractory follicular lymphoma. ASH 2021;Abstract 3528.
Santomasso BD et al. Management of immune-related adverse events in patients treated with chimeric antigen receptor T-cell therapy: ASCO guideline. J Clin Oncol 2021;39(35):3978-92. Abstract
Schuster SJ. Bispecific antibodies for the treatment of lymphomas: Promises and challenges. Hematol Oncol 2021;39(S1):113-6. Abstract
Smith S. Too much and not enough: Revisiting maintenance rituximab in indolent lymphomas. Haematologica 2022;107(2):353-4. Abstract
Smith SM. Evolving strategies for the management of transformed lymphoma. Clin Adv Hematol Oncol 2021;19(10):624-6. Abstract
Smith SM. Improving survival and predicting toxicity in older patients with DLBCL: A delicate balance. J Clin Oncol 2021;39(11):1193-5. Abstract
Straus DJ et al. Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial. Lancet Haematol 2021;8(6):e410-21. Abstract
Thieblemont C et al. Efficacy of tisagenlecleucel in adult patients (pts) with high-risk relapsed/refractory follicular lymphoma (r/r FL): subgroup analysis of the phase II Elara study. ASH 2021;Abstract 131.
Tilly H et al. The POLARIX study: Polatuzumab vedotin with rituximab, cyclophosphamide, doxorubicin, and prednisone (pola-R-CHP) versus rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) therapy in patients with previously untreated diffuse large B-cell lymphoma. ASH 2021;Abstract LBA-1.
Westin JR et al. Efficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed/refractory aggressive B-cell lymphomas: Observations from the JULIET, ZUMA-1, and TRANSCEND trials. Am J Hematol 2021;96(10):1295-312. Abstract